bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Figures S1-S10 Tables S1-S3 from Disulfiram when Combined with Copper Enhances the Therapeutic Effects of Temozolomide for the Treatment of Glioblastoma
Authors: Lun Xueqing , Wells J. Connor , Grinshtein Natalie , King Jennifer C. , Hao Xiaoguang , Dang Ngoc-Ha , Wang Xiuling , Aman Ahmed , Uehling David , Datti Alessandro , Wrana Jeffrey L. , Easaw Jacob C. , Luchman Artee , Weiss Samuel , Cairncross J. Gregory , Kaplan David R. , Robbins Stephen M. , Senger Donna L.
Published: April 2023

Figure S1: Preclinical assessment of clioquinol. Figure S2: Preclinical assessment of montelukast. Figure S3: Secondary validation of compounds identified via HTS. Figure S4: Sensitivity of BTICs to TMZ. Figure S5: Copper is required for Disulfiram-mediated cell killing. Figure S6: Cell Viability and Apoptosis in the presence of DSF-Cu. Figure S7: Efficacy to DSF-Cu is independent of MGMT expression. Figure S8: Inhibition of proteasome activity by DSF-Cu. Figure S9: DSF-Cu in combination with TMZ prolongs survival in vivo. Figure S10: DSF-Cu mediated apoptosis in vivo. Table S1: Summary of BTIC Molecular Characterization. Table S2: Summary of Compound Priortization. Table S3: Down regulation of DNA repair genes by DSF-Cu.
Supplemental Fig.4 from miR-137 and miR-197 Induce Apoptosis and Suppress Tumorigenicity by Targeting MCL-1 in Multiple Myeloma
Authors: Yang Yijun , Li Fei , Saha Manujendra N. , Abdi Jahangir , Qiu Lugui , Chang Hong
Published: April 2023

Supplemental Fig.4. The effect of miR137/197 overexpression on cell viability in MM cells
Supplementary Figure 4 from Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors
Authors: LoRusso Patricia M. , Li Jing , Burger Angelika , Heilbrun Lance K. , Sausville Edward A. , Boerner Scott A. , Smith Daryn , Pilat Mary Jo , Zhang Jie , Tolaney Sara M. , Cleary James M. , Chen Alice P. , Rubinstein Lawrence , Boerner Julie L. , Bowditch Adam , Cai Dongpo , Bell Tracy , Wolanski Andrew , Marrero Allison M. , Zhang Yiping , Ji Jiuping , Ferry-Galow Katherine , Kinders Robert J. , Parchment Ralph E. , Shapiro Geoffrey I.
Published: April 2023

Supplementary Figure S4. Assessment of pNBS1 in the exploratory multiplex immunofluorescence assay.
Appendix 3 from Overdetection of Recurrence after Radical Prostatectomy: Estimates Based on Patient and Tumor Characteristics
Authors: Xia Jing , Trock Bruce J. , Gulati Roman , Mallinger Leslie , Cooperberg Matthew R. , Carroll Peter R. , Carter H. Ballentine , Etzioni Ruth
Published: April 2023

Expression for computing the lower bound on the frequency of overdetection of recurrence.
Supplementary Figure S5 from RhoB Determines Tumor Aggressiveness in a Murine EGFRL858R-Induced Adenocarcinoma Model and Is a Potential Prognostic Biomarker for Lepidic Lung Cancer
Authors: Calvayrac Olivier , Pradines Anne , Raymond-Letron Isabelle , Rouquette Isabelle , Bousquet Emilie , Lauwers-Cances Valérie , Filleron Thomas , Cadranel Jacques , Beau-Faller Michèle , Casanova Anne , Milia Julie , Favre Gilles , Mazières Julien
Published: April 2023

Supplementary Figure S5. Western blot of phospho-ERK1/2 and phospho-Akt from protein lysate of healthy lungs and lung tumors from EGFR/rhob mice, with corresponding quantifications
Supplementary Table 1 from Erlotinib, Erlotinib–Sulindac versus Placebo: A Randomized, Double-Blind, Placebo-Controlled Window Trial in Operable Head and Neck Cancer
Authors: Gross Neil D. , Bauman Julie E. , Gooding William E. , Denq William , Thomas Sufi M. , Wang Lin , Chiosea Simion , Hood Brian L. , Flint Melanie S. , Sun Mai , Conrads Thomas P. , Ferris Robert L. , Johnson Jonas T. , Kim Seungwon , Argiris Athanassios , Wirth Lori , Nikiforova Marina N. , Siegfried Jill M. , Grandis Jennifer R.
Published: April 2023

PDF file - 61KB, Antibodies used to evaluate candidate biomarkers in the TMA.
Legends to supplementary figures and tables from RhoB Determines Tumor Aggressiveness in a Murine EGFRL858R-Induced Adenocarcinoma Model and Is a Potential Prognostic Biomarker for Lepidic Lung Cancer
Authors: Calvayrac Olivier , Pradines Anne , Raymond-Letron Isabelle , Rouquette Isabelle , Bousquet Emilie , Lauwers-Cances Valérie , Filleron Thomas , Cadranel Jacques , Beau-Faller Michèle , Casanova Anne , Milia Julie , Favre Gilles , Mazières Julien
Published: April 2023

Legends to supplementary figures and tables. Contains detailed legends for supplementary figures S1-5 and supplementary tables 1 and 2
supplementary video 2 from Tumor-Produced Interleukin-8 Attracts Human Myeloid-Derived Suppressor Cells and Elicits Extrusion of Neutrophil Extracellular Traps (NETs)
Authors: Alfaro Carlos , Teijeira Alvaro , Oñate Carmen , Pérez Guiomar , Sanmamed Miguel F. , Andueza Maria Pilar , Alignani Diego , Labiano Sara , Azpilikueta Arantza , Rodriguez-Paulete Alfonso , Garasa Saray , Fusco Juan P. , Aznar Angela , Inogés Susana , De Pizzol Maria , Allegretti Marcello , Medina-Echeverz Jose , Berraondo Pedro , Perez-Gracia Jose L. , Melero Ignacio
Published: April 2023

Supplementary video 2. IL-8 induces NET extrusion of GrMDSCs to entrap or adhere HT29 tumor cells. GrMDSCs nuclei were pre-stained with DRAQ5, (cyan), HT29 cells with PKH26 cell membrane dye (Red seen intracellular vesicles) and treated or not with IL-8. The non-cell permeant DNA probe (SYTOXgreen/green) is present in the culture media and only stains DNA when it is extruded extracelullarly. Image on the left shows the complete field of view with several GrMDSCs and an inset of an individual GrMDSC interacting with tumor cells but not extruding NETs since no IL-8 was added to the medium. Image on the left shows the complete microscopy field with several GrMDSCs and an inset with three GrMDSC contacting with HT29 cells and entrapping or adhering to them by formation of the NETs induced upon addition of IL-8. Video is a maximum intensity projection of a Z stack, (DiC is shown for contrast). Video is 300x accelerated.
supplementary figure 6 from Tumor-Produced Interleukin-8 Attracts Human Myeloid-Derived Suppressor Cells and Elicits Extrusion of Neutrophil Extracellular Traps (NETs)
Authors: Alfaro Carlos , Teijeira Alvaro , Oñate Carmen , Pérez Guiomar , Sanmamed Miguel F. , Andueza Maria Pilar , Alignani Diego , Labiano Sara , Azpilikueta Arantza , Rodriguez-Paulete Alfonso , Garasa Saray , Fusco Juan P. , Aznar Angela , Inogés Susana , De Pizzol Maria , Allegretti Marcello , Medina-Echeverz Jose , Berraondo Pedro , Perez-Gracia Jose L. , Melero Ignacio
Published: April 2023

Supplementary figure 6. IL-8 induction of NETs on GrMDSC is dose dependent, similar in intensity to that induced by LPS and can be blocked by IL-8 neutralizing antibodies. (A and B) Experiments as those in figure 6 showing the indicated conditions NET formation induction by LPS and IL-8. (C) GrMDSC induce to extrude NETs by IL-8 or LPS but cocultured with PKH26-labelled (red) HT 29 tumor cells.
Supplementary Figure 3 from Monoclonal Antibodies Targeting LecLex-Related Glycans with Potent Antitumor Activity
Authors: Chua Jia Xin , Vankemmelbeke Mireille , McIntosh Richard S. , Clarke Philip A. , Moss Robert , Parsons Tina , Spendlove Ian , Zaitoun Abid M. , Madhusudan Srinivasan , Durrant Lindy G.
Published: April 2023

Supplementary Figure 3. containing direct cytotoxic activity of FG88.2: PI uptake and WST-8 assay. DNA fragmentation analysis of FG88-treated cells.
supplementary figure 3 from Tumor-Produced Interleukin-8 Attracts Human Myeloid-Derived Suppressor Cells and Elicits Extrusion of Neutrophil Extracellular Traps (NETs)
Authors: Alfaro Carlos , Teijeira Alvaro , Oñate Carmen , Pérez Guiomar , Sanmamed Miguel F. , Andueza Maria Pilar , Alignani Diego , Labiano Sara , Azpilikueta Arantza , Rodriguez-Paulete Alfonso , Garasa Saray , Fusco Juan P. , Aznar Angela , Inogés Susana , De Pizzol Maria , Allegretti Marcello , Medina-Echeverz Jose , Berraondo Pedro , Perez-Gracia Jose L. , Melero Ignacio
Published: April 2023

Supplementary figure 3. Number of MDSC in peripheral blood of patients using osmotic lysis of erythrocytes instead of samples from ficoll-gradient centrifugation. Experiments as those shown in figure 3B representing the percentage of positively stained cells analyzed by FACS merely following osmotic lysis of erythrocytes instead of Ficoll gradient enrichment.
supplementary figure 2 from Tumor-Produced Interleukin-8 Attracts Human Myeloid-Derived Suppressor Cells and Elicits Extrusion of Neutrophil Extracellular Traps (NETs)
Authors: Alfaro Carlos , Teijeira Alvaro , Oñate Carmen , Pérez Guiomar , Sanmamed Miguel F. , Andueza Maria Pilar , Alignani Diego , Labiano Sara , Azpilikueta Arantza , Rodriguez-Paulete Alfonso , Garasa Saray , Fusco Juan P. , Aznar Angela , Inogés Susana , De Pizzol Maria , Allegretti Marcello , Medina-Echeverz Jose , Berraondo Pedro , Perez-Gracia Jose L. , Melero Ignacio
Published: April 2023

Supplementary figure 2. IL-8 hydrodynamic gene transfer effects on tumor free mice. Hydrodynamic gene transfer experiments as in figure 2 but performed in tumor-free mice. Results show the content of the indicated cell subsets in the liver and spleen of euthanized mice.
supplementary figure 1 from Tumor-Produced Interleukin-8 Attracts Human Myeloid-Derived Suppressor Cells and Elicits Extrusion of Neutrophil Extracellular Traps (NETs)
Authors: Alfaro Carlos , Teijeira Alvaro , Oñate Carmen , Pérez Guiomar , Sanmamed Miguel F. , Andueza Maria Pilar , Alignani Diego , Labiano Sara , Azpilikueta Arantza , Rodriguez-Paulete Alfonso , Garasa Saray , Fusco Juan P. , Aznar Angela , Inogés Susana , De Pizzol Maria , Allegretti Marcello , Medina-Echeverz Jose , Berraondo Pedro , Perez-Gracia Jose L. , Melero Ignacio
Published: April 2023

Supplementary figure 1. Comparative spleen size in tumor-free mice and mice engrafted with CT26-GMCSF tumors for 21 days. Photographs taken in parallel upon necropsy of the indicated group of mice.
Supplementary video 1 from Tumor-Produced Interleukin-8 Attracts Human Myeloid-Derived Suppressor Cells and Elicits Extrusion of Neutrophil Extracellular Traps (NETs)
Authors: Alfaro Carlos , Teijeira Alvaro , Oñate Carmen , Pérez Guiomar , Sanmamed Miguel F. , Andueza Maria Pilar , Alignani Diego , Labiano Sara , Azpilikueta Arantza , Rodriguez-Paulete Alfonso , Garasa Saray , Fusco Juan P. , Aznar Angela , Inogés Susana , De Pizzol Maria , Allegretti Marcello , Medina-Echeverz Jose , Berraondo Pedro , Perez-Gracia Jose L. , Melero Ignacio
Published: April 2023

Supplementary video 1. IL-8 induces NET extrusion of GrMDSCs using time-lapse in vivo confocal fluorescence microsocopy. GrMDSCs nuclei were pre-stained with DRAQ5 (Red) and treated with IL-8. The non-cell permeant green DNA probe (SYTOXgreen) is present in the culture media and only stains DNA when is extruded extracelullarly. Video represent over five hours a maximum intensity projection of a Zstack. Video is 600x accelerated
Supplemental Table 2 from Keratin 19, a Cancer Stem Cell Marker in Human Hepatocellular Carcinoma
Authors: Kawai Takayuki , Yasuchika Kentaro , Ishii Takamichi , Katayama Hokahiro , Yoshitoshi Elena Yukie , Ogiso Satoshi , Kita Sadahiko , Yasuda Katsutaro , Fukumitsu Ken , Mizumoto Masaki , Hatano Etsuro , Uemoto Shinji
Published: April 2023

Supplemental Table 2. Primer sequences for PCR, RT-PCR, qPCR, and qRT-PCR
Supplemental Table 1 from Keratin 19, a Cancer Stem Cell Marker in Human Hepatocellular Carcinoma
Authors: Kawai Takayuki , Yasuchika Kentaro , Ishii Takamichi , Katayama Hokahiro , Yoshitoshi Elena Yukie , Ogiso Satoshi , Kita Sadahiko , Yasuda Katsutaro , Fukumitsu Ken , Mizumoto Masaki , Hatano Etsuro , Uemoto Shinji
Published: April 2023

Supplemental Table 1. Clinicopathological findings of HCC patients
Figure S1 and Table S1. from Doxorubicin Synergizes with 34.5ENVE to Enhance Antitumor Efficacy against Metastatic Ovarian Cancer
Authors: Bolyard Chelsea , Yoo Ji Young , Wang Pin-Yi , Saini Uksha , Rath Kellie S. , Cripe Timothy P. , Zhang Jianying , Selvendiran Karuppaiyah , Kaur Balveen
Published: April 2023

Figure S1 and Table S1. Supplementary Figure 1. (A) Typical cobblestone morphology of the ascites derived cancer cells for (deidentified sample 140) under a light microscope, 4X magnification. (B) Fluorescence microscope images for patient ascites derived cancer cells (sample 140) stained with pan-cytokeratin (red); 10X magnification, left; 20X magnification, right. (C) Fluorescence microscope images for patient ascites derived cancer cells (sample 140) stained with vimentin (green); 10X magnification. (D) FACS analysis of patient ascites derived cancer cells stained for vimentin (left) and CD14 (right). M3, total cells; M1, negative for staining; M2, positive for staining. Supplementary Table 1: Table depicting the patient demographics for the collected ascites.
Supplemental Figure legends from Lysyl Oxidase (LOX) Transcriptionally Regulates SNAI2 Expression and TIMP4 Secretion in Human Cancers
Authors: Boufraqech Myriem , Zhang Lisa , Nilubol Naris , Sadowski Samira M. , Kotian Shweta , Quezado Martha , Kebebew Electron
Published: April 2023

This file contains the legends for the supplementary figures
Supplementary Methods from Dual Targeting of Tissue Factor and CD105 for Preclinical PET Imaging of Pancreatic Cancer
Authors: Luo Haiming , England Christopher G. , Shi Sixiang , Graves Stephen A. , Hernandez Reinier , Liu Bai , Theuer Charles P. , Wong Hing C. , Nickles Robert J. , Cai Weibo
Published: April 2023

Determination of NOTA to Fab Fragment Ratio
Online-only supplementary files from (Ir)relevance of Metformin Treatment in Patients with Metastatic Pancreatic Cancer: An Open-Label, Randomized Phase II Trial
Authors: Reni Michele , Dugnani Erica , Cereda Stefano , Belli Carmen , Balzano Gianpaolo , Nicoletti Roberto , Liberati Daniela , Pasquale Valentina , Scavini Marina , Maggiora Paola , Sordi Valeria , Lampasona Vito , Ceraulo Domenica , Di Terlizzi Gaetano , Doglioni Claudio , Falconi Massimo , Piemonti Lorenzo
Published: April 2023

Supplementary table 1. HOMA indexes at baseline among patients according to glucose tolerance Supplementary table 2. Cox proportional hazard models of the predictors of mortality and disease progression by univariate and multivariate analysis Supplementary figure 1. PFS and OS after stratification for baseline glucose, insulin and insulin sensitivity.
Movie S2 from Dual Targeting of Tissue Factor and CD105 for Preclinical PET Imaging of Pancreatic Cancer
Authors: Luo Haiming , England Christopher G. , Shi Sixiang , Graves Stephen A. , Hernandez Reinier , Liu Bai , Theuer Charles P. , Wong Hing C. , Nickles Robert J. , Cai Weibo
Published: April 2023

Movie S2 from Dual Targeting of Tissue Factor and CD105 for Preclinical PET Imaging of Pancreatic Cancer
Supplementary Figure 1 from Intracellular Targeting of the Oncogenic MUC1-C Protein with a Novel GO-203 Nanoparticle Formulation
Authors: Hasegawa Masanori , Sinha Raj Kumar , Kumar Manoj , Alam Maroof , Yin Li , Raina Deepak , Kharbanda Akriti , Panchamoorthy Govind , Gupta Dikshi , Singh Harpal , Kharbanda Surender , Kufe Donald
Published: April 2023

Supplemental Figure S1. GO-203/NPs inhibit NSCLC cell self-renewal.
Supplemental Table S2 from Intracellular Targeting of the Oncogenic MUC1-C Protein with a Novel GO-203 Nanoparticle Formulation
Authors: Hasegawa Masanori , Sinha Raj Kumar , Kumar Manoj , Alam Maroof , Yin Li , Raina Deepak , Kharbanda Akriti , Panchamoorthy Govind , Gupta Dikshi , Singh Harpal , Kharbanda Surender , Kufe Donald
Published: April 2023

Supplemental Table S2. Characterization and physicochemical properties of PLA, PLA-PEG and PLA-(PEG-PPG-PEG) block copolymers and nanoparticles.
Supplemental Table S1 from Intracellular Targeting of the Oncogenic MUC1-C Protein with a Novel GO-203 Nanoparticle Formulation
Authors: Hasegawa Masanori , Sinha Raj Kumar , Kumar Manoj , Alam Maroof , Yin Li , Raina Deepak , Kharbanda Akriti , Panchamoorthy Govind , Gupta Dikshi , Singh Harpal , Kharbanda Surender , Kufe Donald
Published: April 2023

Supplemental Table S1. Loading of GO-203 into PLA, PLA-PEG and PLA-(PEG-PPG-PEG) NPs.
Supplementary Tables S1-3, Figure S1 from Inhibition of JNK Sensitizes Hypoxic Colon Cancer Cells to DNA-Damaging Agents
Authors: Vasilevskaya Irina A. , Selvakumaran Muthu , Hierro Lucia Cabal , Goldstein Sara R. , Winkler Jeffrey D. , O'Dwyer Peter J.
Published: April 2023

Supplementary Tables S1-3, Figure S1. Table S1. Hypoxia increases signaling through JNK in colon cancer cell lines in a cell-specific manner Table S2. Hypoxia increases resistance to chemotherapy in colon cancer cell lines Table S3. Combination of the JNK inhibitor SP600125 with chemotherapy is synergistic in colon cancer cell lines Figure S1. Effects of oxaliplatin and SN-38 on JNK pathway in oxic conditions.
Supplementary Table S3 from Molecular Changes Associated with Acquired Resistance to Crizotinib in ROS1-Rearranged Non–Small Cell Lung Cancer
Authors: Song Ahnah , Kim Tae Min , Kim Dong-Wan , Kim Soyeon , Keam Bhumsuk , Lee Se-Hoon , Heo Dae Seog
Published: April 2023

Supplementary Table S3: Variants identified using whole exome sequencing in crizotinib-resistant tumor.
Supplementary Figures S7-S8 from Molecular Changes Associated with Acquired Resistance to Crizotinib in ROS1-Rearranged Non–Small Cell Lung Cancer
Authors: Song Ahnah , Kim Tae Min , Kim Dong-Wan , Kim Soyeon , Keam Bhumsuk , Lee Se-Hoon , Heo Dae Seog
Published: April 2023

Supplementary Figures S7-S8. Supplementary Figure S7: Cell viability assays in HCC78 and HCC78CR1-2 cells treated with afatinib or in combination with crizotinib. Supplementary Figure S8: Cell viability assays in HCC78 and HCC78CR1-2 cells treated with dacomitinib or in combination with crizotinib.
Supplementary Figure 2 from Sorafenib Inhibition of Mcl-1 Accelerates ATRA-Induced Apoptosis in Differentiation-Responsive AML Cells
Authors: Wang Rui , Xia Lijuan , Gabrilove Janice , Waxman Samuel , Jing Yongkui
Published: April 2023

Combined effects of ATRA with MEK inhibitors in HL-60 cells
Supplementary Figure legends from Molecular Changes Associated with Acquired Resistance to Crizotinib in ROS1-Rearranged Non–Small Cell Lung Cancer
Authors: Song Ahnah , Kim Tae Min , Kim Dong-Wan , Kim Soyeon , Keam Bhumsuk , Lee Se-Hoon , Heo Dae Seog
Published: April 2023

Supplementary Figure Legends
Supplementary Fig S2 from miR-154* and miR-379 in the DLK1-DIO3 MicroRNA Mega-Cluster Regulate Epithelial to Mesenchymal Transition and Bone Metastasis of Prostate Cancer
Authors: Gururajan Murali , Josson Sajni , Chu Gina Chia-Yi , Lu Chia-Lun , Lu Yi-Tsung , Haga Christopher L. , Zhau Haiyen E. , Liu Chunyan , Lichterman Jake , Duan Peng , Posadas Edwin M. , Chung Leland W.K.
Published: April 2023

Supplementary Fig S2. (A) Expression of miR-409-3p and miR-154* assayed by qRT- PCR in ARCaPM-C control PCa cells and ARCaPM-cluster inhibitor transduced cells. Data is normalized to RNU6B. (B) Morphological changes in ARCaPM-cluster inhibitor compared to ARCaPM-C control PCa cells. (C) E-cadherin and N-cadherin mRNA assayed in ARCaPM-C control PCa cells and ARCaPM cluster inhibitor expressing PCa cells by qRT-PCR, normalized to 18s RNA. (D) Invasion assay of in ARCaPM-C and ARCaPM-cluster inhibitor expressing PCa cells. *: p<0.05 was considered to be statistically significant by t-test.
Supplementary Figure 6 from Elevated Coexpression of KITENIN and the ErbB4 CYT-2 Isoform Promotes the Transition from Colon Adenoma to Carcinoma Following APC loss
Authors: Bae Jeong A , Kho Dhong Hyo , Sun Eun Gene , Ko Yoo-Seung , Yoon Somy , Lee Kyung Hwa , Ahn Kyu Youn , Lee Jae Hyuk , Joo Young Eun , Chung Ik Joo , Lee Sug Hyung , Kim Hangun , Kim Kyung Keun
Published: April 2023

Increased expression of ErbB4-CYT-2, but not ErbB4-CYT-1, isoform in human CRC mucosa.
Supplemental Table 1 from Reproducible, Quantitative, and Flexible Molecular Subtyping of Clinical DLBCL Samples Using the NanoString nCounter System
Authors: Veldman-Jones Margaret H. , Lai Zhongwu , Wappett Mark , Harbron Chris G. , Barrett J. Carl , Harrington Elizabeth A. , Thress Kenneth S.
Published: April 2023

Supplemental Table 1. NanoString codeset list comprising 307 genes
Supplementary Figure 2 from Elevated Coexpression of KITENIN and the ErbB4 CYT-2 Isoform Promotes the Transition from Colon Adenoma to Carcinoma Following APC loss
Authors: Bae Jeong A , Kho Dhong Hyo , Sun Eun Gene , Ko Yoo-Seung , Yoon Somy , Lee Kyung Hwa , Ahn Kyu Youn , Lee Jae Hyuk , Joo Young Eun , Chung Ik Joo , Lee Sug Hyung , Kim Hangun , Kim Kyung Keun
Published: April 2023

Characterization of intestinal epithelial tissues from non-TG and KIT-TG mice.
Supplementary Figure 1 from Elevated Coexpression of KITENIN and the ErbB4 CYT-2 Isoform Promotes the Transition from Colon Adenoma to Carcinoma Following APC loss
Authors: Bae Jeong A , Kho Dhong Hyo , Sun Eun Gene , Ko Yoo-Seung , Yoon Somy , Lee Kyung Hwa , Ahn Kyu Youn , Lee Jae Hyuk , Joo Young Eun , Chung Ik Joo , Lee Sug Hyung , Kim Hangun , Kim Kyung Keun
Published: April 2023

Generation of villin-KITENIN transgenic (KIT-TG) mice.
Supplementary Figure S5. from Development of a Model System to Evaluate Local Recurrence in Osteosarcoma and Assessment of the Effects of Bone Morphogenetic Protein-2
Authors: Geller David S. , Singh Michael Y. , Zhang Wendong , Gill Jonathan , Roth Michael E. , Kim Mimi Y. , Xie Xianhong , Singh Christopher K. , Dorfman Howard D. , Villanueva-Siles Esperanza , Park Amy , Piperdi Sajida , Gorlick Richard
Published: April 2023

Supplementary Figure S5. ROC curves for SaOS-2 recurrence vs. average bone margin length.
Supplemental Figure 2 from High Levels of Antibody that Neutralize B-cell Infection of Epstein–Barr Virus and that Bind EBV gp350 Are Associated with a Lower Risk of Nasopharyngeal Carcinoma
Authors: Coghill Anna E. , Bu Wei , Nguyen Hanh , Hsu Wan-Lun , Yu Kelly J. , Lou Pei-Jen , Wang Cheng-Ping , Chen Chien-Jen , Hildesheim Allan , Cohen Jeffrey I.
Published: April 2023

Correlation of anti-gH/gL antibodies with epithelial cell infection neutralization.
Supplementary Figure Legends from Development of a Model System to Evaluate Local Recurrence in Osteosarcoma and Assessment of the Effects of Bone Morphogenetic Protein-2
Authors: Geller David S. , Singh Michael Y. , Zhang Wendong , Gill Jonathan , Roth Michael E. , Kim Mimi Y. , Xie Xianhong , Singh Christopher K. , Dorfman Howard D. , Villanueva-Siles Esperanza , Park Amy , Piperdi Sajida , Gorlick Richard
Published: April 2023

Supplementary Figure Legends
Supplemental Figure 1 from High Levels of Antibody that Neutralize B-cell Infection of Epstein–Barr Virus and that Bind EBV gp350 Are Associated with a Lower Risk of Nasopharyngeal Carcinoma
Authors: Coghill Anna E. , Bu Wei , Nguyen Hanh , Hsu Wan-Lun , Yu Kelly J. , Lou Pei-Jen , Wang Cheng-Ping , Chen Chien-Jen , Hildesheim Allan , Cohen Jeffrey I.
Published: April 2023

Correlation of anti-gp350 antibodies with B-cell infection neutralization.
Supplementary Figure 1 from A Phase I Study of the First-in-Class Antimitochondrial Metabolism Agent, CPI-613, in Patients with Advanced Hematologic Malignancies
Authors: Pardee Timothy S. , Lee King , Luddy John , Maturo Claudia , Rodriguez Robert , Isom Scott , Miller Lance D. , Stadelman Kristin M. , Levitan Denise , Hurd David , Ellis Leslie R. , Harrelson Robin , Manuel Megan , Dralle Sarah , Lyerly Susan , Powell Bayard L.
Published: April 2023

Supplementary Figure 1. Pharmacokinetics of CPI-613 infused over 1 hour. Plasma CPI-613 levels following a 1 or 2 hour infusion shown on day 1 and day 6 on a linear scale. The number of patients in each analysis is indicated by n. **=p<0.05.
Supplementary Table S1 from FDA Approval: Blinatumomab
Authors: Przepiorka Donna , Ko Chia-Wen , Deisseroth Albert , Yancey Carolyn L. , Candau-Chacon Reyes , Chiu Haw-Jyh , Gehrke Brenda J. , Gomez-Broughton Candace , Kane Robert C. , Kirshner Susan , Mehrotra Nitin , Ricks Tiffany K. , Schmiel Deborah , Song Pengfei , Zhao Ping , Zhou Qing , Farrell Ann T. , Pazdur Richard
Published: April 2023

Preferred Terms included in grouped terms
Table S1 from Orchestration and Prognostic Significance of Immune Checkpoints in the Microenvironment of Primary and Metastatic Renal Cell Cancer
Authors: Giraldo Nicolas A. , Becht Etienne , Pagès Franck , Skliris Georgios , Verkarre Virginie , Vano Yann , Mejean Arnaud , Saint-Aubert Nicolas , Lacroix Laetitia , Natario Ivo , Lupo Audrey , Alifano Marco , Damotte Diane , Cazes Aurelie , Triebel Frederic , Freeman Gordon J. , Dieu-Nosjean Marie-Caroline , Oudard Stephane , Fridman Wolf H. , Sautès-Fridman Catherine
Published: April 2023

Table S1. Demographic and clinical characteristics of the analyzed patients are depicted (Mean {plus minus} SD)
Figure S4 from Orchestration and Prognostic Significance of Immune Checkpoints in the Microenvironment of Primary and Metastatic Renal Cell Cancer
Authors: Giraldo Nicolas A. , Becht Etienne , Pagès Franck , Skliris Georgios , Verkarre Virginie , Vano Yann , Mejean Arnaud , Saint-Aubert Nicolas , Lacroix Laetitia , Natario Ivo , Lupo Audrey , Alifano Marco , Damotte Diane , Cazes Aurelie , Triebel Frederic , Freeman Gordon J. , Dieu-Nosjean Marie-Caroline , Oudard Stephane , Fridman Wolf H. , Sautès-Fridman Catherine
Published: April 2023

Figure S4. Inverse relation between TLS and immune checkpoints in primary ccRCC : photomicrographs of immunohistochemistry staining of PD-L1(red)/hematoxylin and TLS structures as revealed by CD3(Blue)DC-Lamp(Red), CD21(Blue)/CD20(Red), and of CD8(red)/hematoxylin in PD-L1+and/orPD-L2+ (A) and PD-L1-/PD-L2- (B) primary ccRCC
Supplementary Table 4 from A Leukemia-Associated CD34/CD123/CD25/CD99+ Immunophenotype Identifies FLT3-Mutated Clones in Acute Myeloid Leukemia
Authors: Angelini Daniela F. , Ottone Tiziana , Guerrera Gisella , Lavorgna Serena , Cittadini Michela , Buccisano Francesco , De Bardi Marco , Gargano Francesca , Maurillo Luca , Divona Mariadomenica , Noguera Nélida I. , Consalvo Maria Irno , Borsellino Giovanna , Bernardi Giorgio , Amadori Sergio , Venditti Adriano , Battistini Luca , Lo-Coco Francesco
Published: April 2023

Supplementary Table 4. MPFC analysis of AML bone marrow sample according to FLT3 or NPM1 mutational status.
Supplementary Table 1 from A Leukemia-Associated CD34/CD123/CD25/CD99+ Immunophenotype Identifies FLT3-Mutated Clones in Acute Myeloid Leukemia
Authors: Angelini Daniela F. , Ottone Tiziana , Guerrera Gisella , Lavorgna Serena , Cittadini Michela , Buccisano Francesco , De Bardi Marco , Gargano Francesca , Maurillo Luca , Divona Mariadomenica , Noguera Nélida I. , Consalvo Maria Irno , Borsellino Giovanna , Bernardi Giorgio , Amadori Sergio , Venditti Adriano , Battistini Luca , Lo-Coco Francesco
Published: April 2023

Supplementary Table 1. anti-human antibodies used.
Supplementary Figure 3 from A Leukemia-Associated CD34/CD123/CD25/CD99+ Immunophenotype Identifies FLT3-Mutated Clones in Acute Myeloid Leukemia
Authors: Angelini Daniela F. , Ottone Tiziana , Guerrera Gisella , Lavorgna Serena , Cittadini Michela , Buccisano Francesco , De Bardi Marco , Gargano Francesca , Maurillo Luca , Divona Mariadomenica , Noguera Nélida I. , Consalvo Maria Irno , Borsellino Giovanna , Bernardi Giorgio , Amadori Sergio , Venditti Adriano , Battistini Luca , Lo-Coco Francesco
Published: April 2023

Supplementary Figure 3. MPFC and molecular analysis of UPN 241 bone marrow samples at diagnosis, during follow-up and at relapse.
Supplementary Figure 2 from A Leukemia-Associated CD34/CD123/CD25/CD99+ Immunophenotype Identifies FLT3-Mutated Clones in Acute Myeloid Leukemia
Authors: Angelini Daniela F. , Ottone Tiziana , Guerrera Gisella , Lavorgna Serena , Cittadini Michela , Buccisano Francesco , De Bardi Marco , Gargano Francesca , Maurillo Luca , Divona Mariadomenica , Noguera Nélida I. , Consalvo Maria Irno , Borsellino Giovanna , Bernardi Giorgio , Amadori Sergio , Venditti Adriano , Battistini Luca , Lo-Coco Francesco
Published: April 2023

Supplementary Figure 2. MPFC detection limit.
Supplementary Tables from Immunologic and Metabolic Features of Pancreatic Ductal Adenocarcinoma Define Prognostic Subtypes of Disease
Authors: Hutcheson Jack , Balaji Uthra , Porembka Matthew R. , Wachsmann Megan B. , McCue Peter A. , Knudsen Erik S. , Witkiewicz Agnieszka K.
Published: April 2023

Statistical analysis of data used to generate Kaplan-Meier curves. Table S1 Cox proportional hazards analysis of indicated FoxP3 expression Table S2 Multivariable Cox proportional hazards analysis of FoxP3 expression and other variables Table S3 Cox proportional hazards analysis of indicated CD163 expression Table S4 Multivariable Cox proportional hazards analysis of CD163 expression and other variables Table S5 Cox proportional hazards analysis and median survival of indicated markers Table S6 Cox proportional hazards analysis of indicated PDL1 expression Table S7 Multivariable Cox proportional hazards analysis of PDL1 expression and other variables Table S8 Cox proportional hazards analysis and median survival of indicated markers Table S9 Cox proportional hazards analysis and median survival of indicated markers Table S10 Cox proportional hazards analysis and median survival of indicated clusters Table S11 Cox proportional hazards analysis and median survival of indicated clusters Table S12 Cox proportional hazards analysis and median survival of indicated clusters Table S13 Cox proportional hazards analysis and median survival of indicated clusters Table S14 Multivariable Cox proportional hazards analysis of clusters and other variables
Supplementary Figure 1 from A Leukemia-Associated CD34/CD123/CD25/CD99+ Immunophenotype Identifies FLT3-Mutated Clones in Acute Myeloid Leukemia
Authors: Angelini Daniela F. , Ottone Tiziana , Guerrera Gisella , Lavorgna Serena , Cittadini Michela , Buccisano Francesco , De Bardi Marco , Gargano Francesca , Maurillo Luca , Divona Mariadomenica , Noguera Nélida I. , Consalvo Maria Irno , Borsellino Giovanna , Bernardi Giorgio , Amadori Sergio , Venditti Adriano , Battistini Luca , Lo-Coco Francesco
Published: April 2023

Supplementary Figure 1. ROC curve analysis using CD34CD123CD25+ve immunophenotype.
Figure S2 from PD-L1 Negative Status is Associated with Lower Mutation Burden, Differential Expression of Immune-Related Genes, and Worse Survival in Stage III Melanoma
Authors: Madore Jason , Strbenac Dario , Vilain Ricardo , Menzies Alexander M. , Yang Jeen Y. H. , Thompson John F. , Long Georgina V. , Mann Graham J. , Scolyer Richard A. , Wilmott James S.
Published: April 2023

PD-L1 and mutation burden in independent validation cohort (n = 16). Results are similar to those observed in the study cohort but not statistically significant (p = 0.12; Kruskal-Wallis).
Supplementary Figures 1 - 5 from Druggable Oncogene Fusions in Invasive Mucinous Lung Adenocarcinoma
Authors: Nakaoku Takashi , Tsuta Koji , Ichikawa Hitoshi , Shiraishi Kouya , Sakamoto Hiromi , Enari Masato , Furuta Koh , Shimada Yoko , Ogiwara Hideaki , Watanabe Shun-ichi , Nokihara Hiroshi , Yasuda Kazuki , Hiramoto Masaki , Nammo Takao , Ishigame Teruhide , Schetter Aaron J. , Okayama Hirokazu , Harris Curtis C. , Kim Young Hak , Mishima Michiaki , Yokota Jun , Yoshida Teruhiko , Kohno Takashi
Published: April 2023

PDF file - 1001KB, S1. Transformation of NIH3T3 cells expressing CD74-NRG1, EZR-ERBB4, or TRIM24-BRAF cDNAs. S2. Electropherogram of Sanger sequencing of cDNAs of novel fusion transcripts. S3. Schematic diagrams of genomic organization for NRG1, ERBB4, BRAF, and RET rearrangements. S4. Break-apart fluorescence in situ hybridization (FISH) for the NRG1 fusion. S5. Representative histological images obtained from fusion-positive IMAs.
Supplemental Table 1 from MR-Guided Near-Infrared Spectral Tomography Increases Diagnostic Performance of Breast MRI
Authors: Mastanduno Michael A. , Xu Junqing , El-Ghussein Fadi , Jiang Shudong , Yin Hong , Zhao Yan , Wang Ke , Ren Fang , Gui Jiang , Pogue Brian W. , Paulsen Keith D.
Published: April 2023

Supplemental Table 1. Complete optical data from 30 analyzed patients.
Supplementary Figures from Inhibition of FoxM1-Mediated DNA Repair by Imipramine Blue Suppresses Breast Cancer Growth and Metastasis
Authors: Rajamanickam Subapriya , Panneerdoss Subbarayalu , Gorthi Aparna , Timilsina Santosh , Onyeagucha Benjamin , Kovalskyy Dmytro , Ivanov Dmitri , Hanes Martha A. , Vadlamudi Ratna K. , Chen Yidong , Bishop Alexander J. , Arbiser Jack L. , Rao Manjeet K.
Published: April 2023

Supplementary Fig. 1. IB inhibits the growth of breast cancer cells in a dose and time dependent manner. Supplementary Fig. 2. IB inhibits migration and invasion of breast cancer cells. Supplementary Fig. 3. IB treatment inhibits in vivo growth and metastasis of breast tumorigenesis. Supplementary Fig. 4. IB is safe and effective against human breast cancers. Supplementary Fig. 5. (A) Western blot analysis of MCF-7 cells treated with vehicle or IB (5μM) using antibodies against FOXM1, SKP2, PLK1 and XRCC3. Supplementary Fig. 6. (A) Western blot analysis of MCF-7 cells treated with vehicle or IB (5μM) using antibodies against cyclin D 1, CDK4, cyclin E2, CDK2. Supplementary Fig. 7. (A) A549, HeLa and DU145 cells were treated with various doses of IB (1-5 μM) for 24 hours and then cells were re-seeded in 6-well plate and allowed to grow for additional 7 days before colonies were stained with crystal violet.
Supplementary Table S1 from Induction of PD-L1 Expression by the EML4–ALK Oncoprotein and Downstream Signaling Pathways in Non–Small Cell Lung Cancer
Authors: Ota Keiichi , Azuma Koichi , Kawahara Akihiko , Hattori Satoshi , Iwama Eiji , Tanizaki Junko , Harada Taishi , Matsumoto Koichiro , Takayama Koichi , Takamori Shinzo , Kage Masayoshi , Hoshino Tomoaki , Nakanishi Yoichi , Okamoto Isamu
Published: April 2023

Supplementary Table S1. Patient characteristics
Supplementary Figure S1 from In Vivo Quantification of Hypoxic and Metabolic Status of NSCLC Tumors Using [18F]HX4 and [18F]FDG-PET/CT Imaging
Authors: Zegers Catharina M.L. , van Elmpt Wouter , Reymen Bart , Even Aniek J.G. , Troost Esther G.C. , Öllers Michel C. , Hoebers Frank J.P. , Houben Ruud M.A. , Eriksson Jonas , Windhorst Albert D. , Mottaghy Felix M. , De Ruysscher Dirk , Lambin Philippe
Published: April 2023

Supplementary Figure S1: Example of the FDG and HX4 parameters (FDG-SUVmean, HX4-SUVmean and HX4-TBR) sub-classified by tumor pathology. Adenocarcinoma (AC), squamous cell carcinoma (SCC), large cell carcinoma (LCC).
Supplementary Materials and Methods, Figures 1 - 14, Table 1 from Molecular Biomarkers of Residual Disease after Surgical Debulking of High-Grade Serous Ovarian Cancer
Authors: Tucker Susan L. , Gharpure Kshipra , Herbrich Shelley M. , Unruh Anna K. , Nick Alpa M. , Crane Erin K. , Coleman Robert L. , Guenthoer Jamie , Dalton Heather J. , Wu Sherry Y. , Rupaimoole Rajesha , Lopez-Berestein Gabriel , Ozpolat Bulent , Ivan Cristina , Hu Wei , Baggerly Keith A. , Sood Anil K.
Published: April 2023

PDF file - 2766KB, Supplementary methods and reports describing all data analyses. Supplementary Table 1. Probesets (N=47) and associated genes (N=38) having consistent differences in expression between residual disease (RD) and No-RD patients in the TCGA and Tothill data sets at a 10 percent false discovery rate in each data set. Figure 1. Bivariate plot of two-sample RD-No RD t-values for TCGA and Tothill. The vast majority of the probesets selected show higher expression in RD cases. Lumican (LUM) is the strongest overall. Figure 2. Zoom on the upper quadrant of the bivariate plot of two-sample RD-No RD t-values for TCGA and Tothill, to show the names more clearly. Figure 3. Heatmap of the TCGA Samples using just the 8 probesets passing the 5 percent FDR filter for both TCGA and Tothill. Figure 4. Heatmap of the Tothill Samples using just the 8 probesets passing the 5 percent FDR filter for both TCGA and Tothill. Figure 5. Heatmap of the TCGA Samples using the 47 probesets passing the 10 percent FDR filter for both TCGA and Tothill. Figure 6. Heatmap of the Tothill Samples using the 47 probesets passing the 10 percent FDR filter for both TCGA and Tothill. Figure 7. Correlations in the TCGA data between the 47 probesets selected by 10 percent FDR cutoffs. Figure 8. Correlations in the Tothill data between the 47 probesets selected by 10 percent FDR cutoffs. Figure 9. Dot and density plots for lumican (LUM) in TCGA and Tothill. Figure 10. Dot and density plots for decorin (DCN) in TCGA and Tothill. Figure 11. Dot and density plots for GADD45B in TCGA and Tothill. Figure 12. Dot and density plots for FABP4 in TCGA and Tothill. Figure 13. Dot and density plots for ADH1B in TCGA and Tothill. Figure 14. Dot and density plots for ADIPOQ in TCGA and Tothill.
Supplemental Table 1 from Targeting IL11 Receptor in Leukemia and Lymphoma: A Functional Ligand-Directed Study and Hematopathology Analysis of Patient-Derived Specimens
Authors: Karjalainen Katja , Jaalouk Diana E. , Bueso-Ramos Carlos , Bover Laura , Sun Yan , Kuniyasu Akihiko , Driessen Wouter H.P. , Cardó-Vila Marina , Rietz Cecilia , Zurita Amado J. , O'Brien Susan , Kantarjian Hagop M. , Cortes Jorge E. , Calin George A. , Koivunen Erkki , Arap Wadih , Pasqualini Renata
Published: April 2023

Supplemental Table 1. Features of synthesized analogs of BMTP-11 for drug-lead optimization.
Video 1 from In Vivo Fluorescence Imaging of the Activity of CEA TCB, a Novel T-Cell Bispecific Antibody, Reveals Highly Specific Tumor Targeting and Fast Induction of T-Cell–Mediated Tumor Killing
Authors: Lehmann Steffi , Perera Ramanil , Grimm Hans-Peter , Sam Johannes , Colombetti Sara , Fauti Tanja , Fahrni Linda , Schaller Teilo , Freimoser-Grundschober Anne , Zielonka Jörg , Stoma Szymon , Rudin Markus , Klein Christian , Umana Pablo , Gerdes Christian , Bacac Marina
Published: April 2023

In vitro live cell confocal imaging of LS174T RFP cells co-cultured with CFSE-labeled T-cells (E:T = 3:1) in the presence of CEA or a control TCB, respectively.
Supplemental Figure Legends from T-Cell Immunoglobulin and ITIM Domain (TIGIT) Associates with CD8+ T-Cell Exhaustion and Poor Clinical Outcome in AML Patients
Authors: Kong Yaxian , Zhu Liuluan , Schell Todd D. , Zhang Jianhong , Claxton David F. , Ehmann W. Christopher , Rybka Witold B. , George Melissa R. , Zeng Hui , Zheng Hong
Published: April 2023

Legends for supplemental figures
Supplementary Information from In Vivo Fluorescence Imaging of the Activity of CEA TCB, a Novel T-Cell Bispecific Antibody, Reveals Highly Specific Tumor Targeting and Fast Induction of T-Cell–Mediated Tumor Killing
Authors: Lehmann Steffi , Perera Ramanil , Grimm Hans-Peter , Sam Johannes , Colombetti Sara , Fauti Tanja , Fahrni Linda , Schaller Teilo , Freimoser-Grundschober Anne , Zielonka Jörg , Stoma Szymon , Rudin Markus , Klein Christian , Umana Pablo , Gerdes Christian , Bacac Marina
Published: April 2023

Supplementary Methods and Figure Legends.
Supplementary Figures from In Vivo Fluorescence Imaging of the Activity of CEA TCB, a Novel T-Cell Bispecific Antibody, Reveals Highly Specific Tumor Targeting and Fast Induction of T-Cell–Mediated Tumor Killing
Authors: Lehmann Steffi , Perera Ramanil , Grimm Hans-Peter , Sam Johannes , Colombetti Sara , Fauti Tanja , Fahrni Linda , Schaller Teilo , Freimoser-Grundschober Anne , Zielonka Jörg , Stoma Szymon , Rudin Markus , Klein Christian , Umana Pablo , Gerdes Christian , Bacac Marina
Published: April 2023

Supplementary Figure S1. CEA TCB leads stimulates the expression of CD25, a T-cell activation marker, on both T-helper (CD4+) and cytotoxic T-cells (CD8+) after incubation with LS174T tumor cells. Supplementary Figure S2. CEA TCB induces efficient MKN45 tumor cell lysis and T-cell activation in the presence of these tumor cells. Supplementary Figure S3. Both CD4+ and CD8+ T-cells contribute to CEA-TCB mediated killing. Supplementary Figure S4. Ex vivo analysis of in vivo tumor targeting. Supplementary Figure S5. Analysis of T-cell migratory persistence index.
Supplementary Figure 1 from Polymorphisms in MIR27A Associated with Early-Onset Toxicity in Fluoropyrimidine-Based Chemotherapy
Authors: Amstutz Ursula , Offer Steven M. , Sistonen Johanna , Joerger Markus , Diasio Robert B. , Largiadèr Carlo R.
Published: April 2023

Supplementary Figure 1: Allele frequencies of rs895819 for different toxicity types in patients without DPYD risk variants
Additional Table I from Minimal Residual Disease after Conventional Treatment Significantly Impacts on Progression-Free Survival of Patients with Follicular Lymphoma: The FIL FOLL05 Trial
Authors: Galimberti Sara , Luminari Stefano , Ciabatti Elena , Grassi Susanna , Guerrini Francesca , Dondi Alessandra , Marcheselli Luigi , Ladetto Marco , Piccaluga Pier Paolo , Gazzola Anna , Mannu Claudia , Monitillo Luigia , Mantoan Barbara , Del Giudice Ilaria , Della Starza Irene , Cavalli Marzia , Arcaini Luca , Tucci Alessandra , Palumbo Giuseppe Alberto , Rigacci Luigi , Pulsoni Alessandro , Vitolo Umberto , Boccomini Carola , Vallisa Daniele , Bertoldero Giovanni , Gaidano Gianluca , Musto Pellegrino , Petrini Mario , Federico Massimo
Published: April 2023

Cox proportional hazard Models for PFS: role of the molecular tumor burden at diagnosis.
Supplemental Figure 1 from Stromal CD8+ T-cell Density—A Promising Supplement to TNM Staging in Non–Small Cell Lung Cancer
Authors: Donnem Tom , Hald Sigurd M. , Paulsen Erna-Elise , Richardsen Elin , Al-Saad Samer , Kilvaer Thomas K. , Brustugun Odd Terje , Helland Aslaug , Lund-Iversen Marius , Poehl Mette , Olsen Karen Ege , Ditzel Henrik J. , Hansen Olfred , Al-Shibli Khalid , Kiselev Yury , Sandanger Torkjel M. , Andersen Sigve , Pezzella Francesco , Bremnes Roy M. , Busund Lill-Tove
Published: April 2023

Supplemental Figure 1. Disease-specific survival curves according to low, intermediate and high stromal CD8+ T-cell density in the Danish cohort (Odense University Hospital, n = 178). (A) Score from the invasive margin tumor area, (B) score from the central parts of the tumor. The maximum score for each patient was used.
Supplemental Figure 3 from The Hippo Coactivator YAP1 Mediates EGFR Overexpression and Confers Chemoresistance in Esophageal Cancer
Authors: Song Shumei , Honjo Soichiro , Jin Jiankang , Chang Shih-Shin , Scott Ailing W. , Chen Qiongrong , Kalhor Neda , Correa Arlene M. , Hofstetter Wayne L. , Albarracin Constance T. , Wu Tsung-Teh , Johnson Randy L. , Hung Mien-Chie , Ajani Jaffer A.
Published: April 2023

Supplemental Figure 3. Effect of the combination of YAP1 inhibitor VP, EGFR inhibitor Erlotinib and 5-FU on EC cell growth
Supplementary Table S2 from The Bromodomain Inhibitor JQ1 and the Histone Deacetylase Inhibitor Panobinostat Synergistically Reduce N-Myc Expression and Induce Anticancer Effects
Authors: Shahbazi Jeyran , Liu Pei Y. , Atmadibrata Bernard , Bradner James E. , Marshall Glenn M. , Lock Richard B. , Liu Tao
Published: April 2023

JQ1 and panobinostat synergistically modulate gene expression.
Supplementary Figure 1 from Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors
Authors: Ortiz-Cuaran Sandra , Scheffler Matthias , Plenker Dennis , Dahmen llona , Scheel Andreas H. , Fernandez-Cuesta Lynnette , Meder Lydia , Lovly Christine M. , Persigehl Thorsten , Merkelbach-Bruse Sabine , Bos Marc , Michels Sebastian , Fischer Rieke , Albus Kerstin , König Katharina , Schildhaus Hans-Ulrich , Fassunke Jana , Ihle Michaela A. , Pasternack Helen , Heydt Carina , Becker Christian , Altmüller Janine , Ji Hongbin , Müller Christian , Florin Alexandra , Heuckmann Johannes M. , Nuernberg Peter , Ansén Sascha , Heukamp Lukas C. , Berg Johannes , Pao William , Peifer Martin , Buettner Reinhard , Wolf Jürgen , Thomas Roman K. , Sos Martin L.
Published: April 2023

Activation of ERBB2 or MET leads to decreased sensitivity to AZD9291 and rociletinib.
Figure S4 from A Novel E2F/Sphingosine Kinase 1 Axis Regulates Anthracycline Response in Squamous Cell Carcinoma
Authors: Hazar-Rethinam Mehlika , de Long Lilia Merida , Gannon Orla M. , Topkas Eleni , Boros Samuel , Vargas Ana Cristina , Dzienis Marcin , Mukhopadhyay Pamela , Simpson Fiona , Endo-Munoz Liliana , Saunders Nicholas A.
Published: April 2023

Figure S4. Validation of siRNA directed against E2F7 and E2F1 mRNA expression level in SCC25 cells in which E2F7 had been silenced by siRNA.
Figure S3 from A Novel E2F/Sphingosine Kinase 1 Axis Regulates Anthracycline Response in Squamous Cell Carcinoma
Authors: Hazar-Rethinam Mehlika , de Long Lilia Merida , Gannon Orla M. , Topkas Eleni , Boros Samuel , Vargas Ana Cristina , Dzienis Marcin , Mukhopadhyay Pamela , Simpson Fiona , Endo-Munoz Liliana , Saunders Nicholas A.
Published: April 2023

Figure S3. Cytotoxic responses to doxorubicin selectively enhanced in E2F7-deficient murine keratinocytes.
Supplementary Tables 1 - 3 from Activity of MM-398, Nanoliposomal Irinotecan (nal-IRI), in Ewing's Family Tumor Xenografts Is Associated with High Exposure of Tumor to Drug and High SLFN11 Expression
Authors: Kang Min H. , Wang Jing , Makena Monish R. , Lee Joo-Sang , Paz Nancy , Hall Connor P. , Song Michael M. , Calderon Ruben I. , Cruz Riza E. , Hindle Ashly , Ko Winford , Fitzgerald Jonathan B. , Drummond Daryl C. , Triche Timothy J. , Reynolds C. Patrick
Published: April 2023

Supplementary Table 1. Human EFT, RMS, and NB cell lines used for current study. Supplementary Table 2. Median Survival of xenograft mice bearing human pediatric cancer treated with irinotecan or nal-IRI. Supplementary Table 3. Pharmacokinetic variables for irinotecan and nal-IRI following intravenous injections in mice.
Supplementary Material and Methods clean from RING-Finger Protein 6 Amplification Activates JAK/STAT3 Pathway by Modifying SHP-1 Ubiquitylation and Associates with Poor Outcome in Colorectal Cancer
Authors: Liang Qian , Ma Dan , Zhu Xiaoqiang , Wang Zhenhua , Sun Tian-Tian , Shen Chaoqin , Yan Tingting , Tian Xianglong , Yu TaChung , Guo Fangfang , Tang JiaYin , Lin Yanwei , Chen Huimin , Zhou Chao , Ge Zhizheng , Zhong Ming , Chen Jinxian , Liu Qiang , Wang Zheng , Fang Jing-Yuan , Chen Haoyan , Hong Jie
Published: April 2023

Supplementary Material and Methods clean
Supplementary Material from BCAM and LAMA5 Mediate the Recognition between Tumor Cells and the Endothelium in the Metastatic Spreading of KRAS-Mutant Colorectal Cancer
Authors: Bartolini Alice , Cardaci Sabrina , Lamba Simona , Oddo Daniele , Marchiò Caterina , Cassoni Paola , Amoreo Carla Azzurra , Corti Giorgio , Testori Alessandro , Bussolino Federico , Pasqualini Renata , Arap Wadih , Corà Davide , Di Nicolantonio Federica , Marchiò Serena
Published: April 2023

The supplementary material includes Supplementary Methods, two Supplementary Tables, and six Supplementary Figures Table S1. Complete set of BCAM-mimic peptides. Table S2. Characterization of human CRC cell lines in animal models. Figure S1. Quality control of the phage display experiments: sequencing readout. Figure S2. BCAM protein expression in the complete panel of human hepatic metastases. Figure S3. BCAM protein expression in human primary CRCs. Figure S4. BCAM protein and mRNA expression in all cell lines. Figure S5. Photographic documentation of the experimental hepatic metastasis models. Figure S6. HT-55, DLD-1, LIM1215 and SW-48 cells cannot be reduced to adhesion-functional monocellular suspensions.
Supplemental Material and Methods from PKCα Attenuates Jagged-1–Mediated Notch Signaling in ErbB-2–Positive Breast Cancer to Reverse Trastuzumab Resistance
Authors: Pandya Kinnari , Wyatt Debra , Gallagher Brian , Shah Deep , Baker Andrew , Bloodworth Jeffrey , Zlobin Andrei , Pannuti Antonio , Green Andrew , Ellis Ian O. , Filipovic Aleksandra , Sagert Jason , Rana Ajay , Albain Kathy S. , Miele Lucio , Denning Mitchell F. , Osipo Clodia
Published: April 2023

Materials and Methods
Figure S4 from PKCα Attenuates Jagged-1–Mediated Notch Signaling in ErbB-2–Positive Breast Cancer to Reverse Trastuzumab Resistance
Authors: Pandya Kinnari , Wyatt Debra , Gallagher Brian , Shah Deep , Baker Andrew , Bloodworth Jeffrey , Zlobin Andrei , Pannuti Antonio , Green Andrew , Ellis Ian O. , Filipovic Aleksandra , Sagert Jason , Rana Ajay , Albain Kathy S. , Miele Lucio , Denning Mitchell F. , Osipo Clodia
Published: April 2023

Kaplan-Meier Plotter analyses of recurrence free survival of ErbB2 positive breast cancer patients with PRKCA, HEY1 expression.